secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0000805928-26-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q4 revenue $59.9M (+21%); FY2025 $225.2M; guides 2026 growth >=18%
-------------------------------------------------------------------------

- Q4 revenue $59.9M (+21.3% YoY); net loss $13.2M ($0.28/sh); adjusted net income $3.5M ($0.07/sh).
- FY2025 revenue $225.2M (+20.2% YoY); adjusted net income $14.4M ($0.29/sh); adjusted EBITDA $27.9M.
- FDA approved Avance BLA on Dec 3, 2025; CMS new Level 3 code raises Avance facility reimbursement 40% to $8,965.
- Closed upsized public offering of 4.6M shares for $133.3M net; $69.7M used to repay Oberland loan facility.
- 2026 guidance: revenue at least $265.7M (+18% YoY); gross margin 74%-76%; expects positive free cash flow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592826000028/0000805928-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592826000028/axgn-20260224.htm
  HTML page:      https://secwatch.observer/filing/0000805928-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer